Pila Pharma AB (publ) (STO:PILA)

Market Cap	122.26M
Revenue (ttm)	789.89K
Net Income (ttm)	-11.24M
Shares Out	42.08M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,542
Average Volume	92,416
Open	3.345
Previous Close	3.050
Day's Range	2.740 - 3.345
52-Week Range	2.400 - 7.180
Beta	0.58
RSI	41.67
Earnings Date	Aug 27, 2025

About Pila Pharma AB

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PILA

Financial Performance

In 2024, Pila Pharma AB's revenue was 789,889, a decrease of -46.01% compared to the previous year's 1.46 million. Losses were -11.24 million, 13.2% more than in 2023.